trending Market Intelligence /marketintelligence/en/news-insights/trending/sbpmecgcaeajqqzgoadeqa2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Roche partners with biotech startup for soil-based drug discovery

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Roche partners with biotech startup for soil-based drug discovery

Swiss drugmaker Roche Holding AG is collaborating with New York-based biotech startup Lodo Therapeutics Corp. to discover natural products directly from the microbial DNA sequence information contained in soil.

Lodo will receive an undisclosed up-front payment and could receive milestone payments up to $969 million. Lodo is also eligible to receive tiered-royalties on sales of certain products resulting from the partnership.

Roche's California-based unit Genentech Inc. will use Lodo's proprietary genome mining and biosynthetic cluster assembly platform to identify molecules with therapeutic potential against multiple disease-related targets.

Lodo said the gene-based approach is expected to reduce the time and cost of drug discovery.

Instead of culturing known strains of bacteria in the laboratory, the companies will look for natural products in soil that comprise a significant proportion of the small molecule drugs used to treat cancer, infections and chronic illnesses such as type 2 diabetes.